Health Care [ 5/12 ] | Biotechnology [ 33/74 ]
NASDAQ | Common Stock
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.
Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 26 | -0.85 Decreased by -3.66% | -1.10 Increased by +22.93% |
| Mar 9, 26 | -1.43 Decreased by -76.54% | -1.03 Decreased by -38.65% |
| Nov 5, 25 | -0.97 Decreased by -34.72% | -0.55 Decreased by -76.36% |
| Aug 7, 25 | -0.88 Decreased by -72.55% | -0.53 Decreased by -66.04% |
| May 7, 25 | -0.82 Decreased by -51.85% | -0.71 Decreased by -15.49% |
| Mar 19, 25 | -0.81 Decreased by -14.08% | -0.76 Decreased by -6.58% |
| Nov 7, 24 | -0.72 Increased by +80.95% | -0.59 Decreased by -22.03% |
| Aug 8, 24 | -0.51 Increased by +41.13% | -0.55 Increased by +7.27% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 463.00 K Decreased by -60.19% | -40.83 M Decreased by -38.37% | Decreased by -8.82 K% Decreased by -247.57% |
| Dec 31, 25 | 284.00 K Decreased by -78.58% | 97.91 M Increased by +444.25% | Increased by +34.47 K% Increased by +1.71 K% |
| Sep 30, 25 | 396.00 K Decreased by -81.77% | -36.77 M Decreased by -46.04% | Decreased by -9.28 K% Decreased by -701.03% |
| Jun 30, 25 | 193.00 K Decreased by -89.64% | -31.63 M Decreased by -79.64% | Decreased by -16.39 K% Decreased by -1.63 K% |
| Mar 31, 25 | 1.16 M Increased by +33.07% | -29.51 M Decreased by -114.66% | Decreased by -2.54 K% Decreased by -61.32% |
| Dec 31, 24 | 1.33 M Increased by +190.15% | -28.44 M Decreased by -169.24% | Decreased by -2.14 K% Increased by +7.21% |
| Sep 30, 24 | 2.17 M Increased by +135.06% | -25.17 M Decreased by -70.52% | Decreased by -1.16 K% Increased by +27.46% |
| Jun 30, 24 | 1.86 M Increased by +92.26% | -17.61 M Decreased by -58.05% | Decreased by -945.09% Increased by +17.79% |